Archiv
Archiv anzeigen:
bis


Metformin for Sickle Cell Patients with Diabetes

Brady L. Stein, MD, MHS reviewing Badawy SM and Payne AB. Blood Adv 2019 Nov 1

Metformin use is associated with reductions in sickle-cell–related adverse events as well as in inpatient and emergency department visits.


Haploidentical Stem Cell Transplantation for Hematologic Cancers

Michael E. Williams, MD, ScM reviewing Gagelmann N et al. JAMA Oncol 2019 Oct 17

Mortality outcomes with haploidentical-donor SCT followed by cyclophosphamide were improved compared with mismatched-unrelated–donor SCT.


Managing Pregnancy in Women with Myeloproliferative Neoplasms

Brady L. Stein, MD, MHS reviewing Maze D et al. JAMA Netw Open 2019 Oct 2

Aspirin and interferon improved live birth rates among pregnant women with essential thrombocythemia or polycythemia vera.


Front-Line Immunotherapy for Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Paz-Ares L et al. Lancet 2019 Oct 4, Goetze TO. Lancet 2019 Oct 4

Adding durvalumab to chemotherapy significantly improved overall survival.


Nivolumab plus Ipilimumab for Advanced NSCLC: Updated Survival Results

Anne S. Tsao, MD reviewing Hellmann MD et al. N Engl J Med 2019 Sep 28

Overall survival was improved versus chemotherapy in non–small-cell lung cancer patients, independent of their PD-L1 status or tumor mutational burden.


Rivaroxaban vs. Vitamin K Antagonists for Antiphospholipid Antibody Syndrome

Brady L. Stein, MD, MHS reviewing Ordi-Ros J et al. Ann Intern Med 2019 Oct 15, Wahl D and Dufrost V. Ann Intern Med 2019 Oct 15

Rivaroxaban failed to demonstrate noninferiority to VKAs in preventing recurrent thrombosis.


BRAF-Targeted Therapy for BRAF V600E-Mutant Metastatic Colorectal Cancer

David H. Ilson, MD, PhD reviewing Kopetz S et al. N Engl J Med 2019 Sep 30

The combination of cetuximab and encorafenib, with or with or without binimetinib, significantly improved survival versus standard therapy.


ESMO 2019 Report — Breast Cancer

William J. Gradishar, MD

Highlights of the latest treatments


Factors Influencing Hemoglobin Increments After Transfusion

Brady L. Stein, MD, MHS reviewing Roubinian NH et al. Blood 2019 Sep 26

Transfusion efficacy was influenced by gender, donor age, irradiation, apheresis collection, storage duration, and Rh-D positivity.


MYC Rearrangement and Prognosis in Diffuse Large B-Cell Lymphoma

Michael E. Williams, MD, ScM reviewing Rosenwald A et al. J Clin Oncol 2019 Sep 9

Isolated MYC gene rearrangement had minimal negative prognostic impact compared with double- or triple-hit lymphoma.


Archiv
Seite von 86
Editorial Member Board Empfehlungen

Dr. med. Richard Herrmann

Prof. em. für Onkologie Universitätsspital Basel

E-Mail: E-Mail anzeigen

Liebe Kolleginnen und Kollegen!

Die Zahl der veröffentlichten Studien, die für die Betreuung unserer Tumorpatienten von Bedeutung sind, ist kaum mehr überschaubar. Hier hilft uns die Selektion des Teams von Journal Watch. Mit dieser neuen Serie soll eine weitere Auswahl getroffen werden. Diese ist, wie wohl auch die vorgenannte, nicht ohne Subjektivität. Für die Auswahl wichtig war mir ganz besonders die Praxisrelevanz.

Kommentar weiterlesen

Apalutamide for Castration-Resistant PSA-Only Prostate Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Smith MR et al. N Engl J Med 2018 Feb 8

Metastasis-free survival was significantly longer with apalutamide than with placebo.


Second-Line Olaparib for Gastric Cancer

David H. Ilson, MD, PhD reviewing Bang Y-J et al. Lancet Oncol 2017 Dec

Contrary to prior findings, adding olaparib to paclitaxel failed to improve survival in patients with disease progression following chemotherapy.


Predicting Response to Immunotherapy in Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Rizvi H et al. J Clin Oncol 2018 Jan 16

Assessment of tumor mutation burden using targeted next-generation sequencing may be predictive of benefit from PD-1 and PD-L1 inhibitors.


Prolonged Adjuvant Aromatase Inhibitor Treatment for Early Breast Cancer

William J. Gradishar, MD reviewing Blok EJ et al. J Natl Cancer Inst 2018 Jan 1, Goldvaser H et al. J Natl Cancer Inst 2018 Jan 1, Pohlmann PR and Isaacs C. J Natl Cancer Inst 2018 Jan 1

Outcomes were not superior with 5 versus 2.5 years of extended letrozole therapy.


Prognosis of Monoclonal Gammopathy of Undetermined Significance

David Green, MD, PhD reviewing Kyle RA et al. N Engl J Med 2018 Jan 18

Overall survival was significantly shorter among MGUS patients than among a matched control population in a long-term follow-up study.


Prognosis for BRCA-Mutated Breast Cancer

William J. Gradishar, MD reviewing Copson ER et al. Lancet Oncol 2018 Jan 11

Survival is similar between BRCA mutation carriers versus those with sporadic disease.


Electrical Field Therapy for Glioblastoma

Roy E. Strowd, MD reviewing Stupp R et al. JAMA 2017 Dec 19

Adding tumor-treating electrical-field therapy to maintenance temozolomide chemotherapy significantly improved survival in patients with newly diagnosed glioblastoma.


Atezolizumab for Advanced Urothelial Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Powles T et al. Lancet 2017 Dec 18, Massari F and Di Nunno V. Lancet 2017 Dec 18

Overall survival was not improved with the PD-L1 inhibitor atezolizumab versus chemotherapy in patients with highest PD-L1 expression.


Pembrolizumab for Cisplatin-Ineligible Patients with Advanced Urothelial Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Balar AV et al. Lancet Oncol 2017 Sep 26

First-line therapy demonstrated antitumor activity in a phase II study.


Restarting Adjuvant Endocrine Therapy for Breast Cancer

William J. Gradishar, MD reviewing He W et al. J Natl Cancer Inst 2017 Oct 01

Disease-free survival is significantly improved in patients who restart therapy versus those who do not restart after discontinuation.